Sharon Leung1, Reha Pokharel, Michelle N Gong. 1. Division of Critical Care Medicine, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA. sleung@montefiore.org
Abstract
OBJECTIVE: The pleiotropic effects of statins, 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor, have been shown to modify inflammatory cell signaling on the immune response to infection. It was postulated that statins may be a good candidate as novel therapeutic agents for the treatment of sepsis. We investigated whether ongoing statin therapy is associated with mortality in patients with bloodstream infection. DESIGN: A retrospective cohort study. SETTING: Two tertiary hospitals in Bronx, NY. PATIENTS: Adult patients in the hospital with bloodstream infection and categorized according to statin therapy as an outpatient or inpatient before bacteremia. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: Of 2,139 bacteremic hospitalized patients, 592 (28%) received statins before blood cultures and 677 (32%) died within 90 days. On multivariate adjustment, the association between statin therapy and 90-day all-cause mortality was statistically significant (hazard ratio, 0.78; 95% confidence interval [CI] 0.65-0.94), but statin users and nonusers differed significantly on many baseline clinical factors. Using the propensity score matched analysis to balance the differences between groups, the association was no longer significant (hazard ratio 0.99; 95% CI 0.77-1.25). Multivariate analysis after stratifying by decile in propensity score for statin use demonstrated similar results (hazard ratio 0.86; 95% CI 0.70-1.06). Statin use was not associated with reduced intensive care unit admission (odds ratio [OR], 0.86; 95% CI 0.59-1.26), hospital length of stay (β = -0.8 days; 95% CI -2.2 to 1.7 days), intensive care unit length of stay (β = -0.1 days; 95% CI -3.7 to 3.8 days), or need for mechanical or noninvasive ventilation (OR 1.03; 95% CI 0.70-1.51). CONCLUSION: After adjusting for the propensity to receive statin therapy, no statistically significant association between statin therapy before bloodstream infection and survival was identified.
OBJECTIVE: The pleiotropic effects of statins, 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor, have been shown to modify inflammatory cell signaling on the immune response to infection. It was postulated that statins may be a good candidate as novel therapeutic agents for the treatment of sepsis. We investigated whether ongoing statin therapy is associated with mortality in patients with bloodstream infection. DESIGN: A retrospective cohort study. SETTING: Two tertiary hospitals in Bronx, NY. PATIENTS: Adult patients in the hospital with bloodstream infection and categorized according to statin therapy as an outpatient or inpatient before bacteremia. INTERVENTIONS: None. MEASUREMENT AND MAIN RESULTS: Of 2,139 bacteremic hospitalized patients, 592 (28%) received statins before blood cultures and 677 (32%) died within 90 days. On multivariate adjustment, the association between statin therapy and 90-day all-cause mortality was statistically significant (hazard ratio, 0.78; 95% confidence interval [CI] 0.65-0.94), but statin users and nonusers differed significantly on many baseline clinical factors. Using the propensity score matched analysis to balance the differences between groups, the association was no longer significant (hazard ratio 0.99; 95% CI 0.77-1.25). Multivariate analysis after stratifying by decile in propensity score for statin use demonstrated similar results (hazard ratio 0.86; 95% CI 0.70-1.06). Statin use was not associated with reduced intensive care unit admission (odds ratio [OR], 0.86; 95% CI 0.59-1.26), hospital length of stay (β = -0.8 days; 95% CI -2.2 to 1.7 days), intensive care unit length of stay (β = -0.1 days; 95% CI -3.7 to 3.8 days), or need for mechanical or noninvasive ventilation (OR 1.03; 95% CI 0.70-1.51). CONCLUSION: After adjusting for the propensity to receive statin therapy, no statistically significant association between statin therapy before bloodstream infection and survival was identified.
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: Marc W Merx; Elisa A Liehn; Jürgen Graf; Annette van de Sandt; Maren Schaltenbrand; Jürgen Schrader; Peter Hanrath; Christian Weber Journal: Circulation Date: 2005-07-05 Impact factor: 29.690
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Johannes Pleiner; Georg Schaller; Friedrich Mittermayer; Stefan Zorn; Claudia Marsik; Stefan Polterauer; Stylianos Kapiotis; Michael Wolzt Journal: Circulation Date: 2004-11-01 Impact factor: 29.690
Authors: Peter S Kruger; Meg L Harward; Mark A Jones; Christopher J Joyce; Karam M Kostner; Michael S Roberts; Bala Venkatesh Journal: Am J Respir Crit Care Med Date: 2010-10-19 Impact factor: 21.405
Authors: Reimar W Thomsen; Heidi H Hundborg; Søren P Johnsen; Lars Pedersen; Henrik T Sørensen; Henrik C Schønheyder; Hans-Henrik Lervang Journal: Crit Care Med Date: 2006-04 Impact factor: 7.598
Authors: Aisling R Caffrey; Tristan T Timbrook; Eunsun Noh; George Sakoulas; Steven M Opal; Victor Nizet; Kerry L LaPlante Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191
Authors: John P Magulick; Christopher R Frei; Sayed K Ali; Eric M Mortensen; Mary Jo Pugh; Christine U Oramasionwu; Kelly R Daniels; Ishak A Mansi Journal: Am J Med Sci Date: 2014-03 Impact factor: 2.378
Authors: Henry E Wang; Russell Griffin; Nathan I Shapiro; George Howard; Monika M Safford Journal: J Intensive Care Med Date: 2014-09-15 Impact factor: 3.510
Authors: Daniel R Ouellette; Erics Espinoza Moscoso; Julio Pinto Corrales; Michael Peters Journal: Ann Intensive Care Date: 2015-05-06 Impact factor: 6.925